Kumar, Riten

AbstractTo evaluate the correlation between an uncapped, actual body weight‐based unfractionated heparin dosing strategy, we performed a body mass index‐based subanalysis of a previously reported pediatric cohort. Nearly half (45%) of obese patients were supra‐therapeutic on initial anti‐FXa assessment. Obese patients achieved therapeutic anti‐FXa significantly faster than nonobese patients (median 4 vs 12 hours, P = .0192) and were more likely to have any supra‐therapeutic anti‐FXa levels (77% vs 35%; P = .0021). There was no statistically significant difference in major or clinically relevant nonmajor bleeding rates between weight categories (P = .69). Prospective pediatric studies are warranted to confirm our findings.